PGR and breast neoplasm: Herein, we used targeted genomic, proteomic, and Zn profiling in breast tumors and malignant cell lines that have characteristic features of Luminal (low-invasive, ER+/PR+/HER2−; T47D cells) and Basal (highly invasive, ER−/PR−/HER2−; MDA-MB-231 cells) subtypes.